(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 February 2003 (13.02.2003)

PCT

(10) International Publication Number
WO 03/011903 A2

(51) International Patent Classification[7]: C07K 14/47, 16/18, A61K 39/00, 39/395

(21) International Application Number: PCT/IT02/00490

(22) International Filing Date: 25 July 2002 (25.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/IT01/00413 27 July 2001 (27.07.2001) IT

(71) Applicant *(for all designated States except US)*: **KENTON S.R.L.** [IT/IT]; Via Treviso, 4, I-00040 Pomezia (IT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FELICI, Franco** [IT/IT]; Via Treviso, 4, I-00040 Pomezia (IT). **MINENKOVA, Olga** [RU/IT]; Via Treviso, 4, I-00040 Pomezia (IT).

(74) Agents: **SPADARO, Marco** et al.; Viale dei Parioli, 160, I-00197 Roma (IT).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** IDENTIFICATION OF SPECIFIC TUMOR ANTIGENS BY MEANS OF THE SELECTION OF CDNA LIBRARIES WITH SERA AND THE USE OF SAID ANTIGENA IN THE TREATMENT OF TUMORS



(57) **Abstract:** A method is described for the identification of specific tumour antigens by means of the selection of CND display libraries by using sera, characterised in that said selection is accomplished with the phage display technique, and in particular said selection is accomplished by means of the SEREX technique (serological analysis of autologous tumor antigens through the expression of recombinant cDNA). The method according to the invention described herein advantageously combines the SEREX approach with the potency of the phage display technique defined above, at the same time avoiding the drawbacks characteristic of the SEREX technique. The so identified antigens are useful for the preparation of medicaments for the treatment of tumors.

WO 03/011903 A2

Identification of specific tumor antigens by means of the selection of cDNA libraries with sera and the use of said antigens in the treatment of tumors

The invention described herein relates to a method for the identification of specific tumor antigens by means of selection with sera of cDNA libraries derived from tumor cell lines or from subjects suffering from tumors, and particularly for the therapy of tumors.

The invention described herein provides compounds, methods for their preparation, methods for their use, and compositions containing them, suitable for industrial application in the pharmaceutical field.

In particular, but not exclusively, the invention described herein relates to the field of tumor treatment.

Background to the invention

Tumor therapy is practised according to multiple approaches of tumor attack. Other then the use of cytotoxic substances, immunotherapeutic approach is gaining even higher interest.

In this context, tumor immunotherapy knows a constant increase of efforts in research, with the aim to find more effective methods for the identification of specific tumor antigens, useful for the preparation of medicaments for the treatment of tumors. In particular, antitumor vaccines constitute a kind of immunotherapy having the goal to stimulate immune system of the same patient to react against tumor antigens. For this reason, the research has recently focused also on the target of identifying, isolating and cloning specific tumor-associated antigens, which can be recognized by the host immune system.

A review of arguments and related problems can be found, for example in EP 0 496 074 and WO 00/25813 and the references cited therein.

The identification of tumor antigens may then provide new and better target-specific therapeutic means and more effective methods for the treatment of tumors. More or less specific tumor antigens are known, which have been obtained using tumor cells as antigens-immunogens to stimulate antibodies in laboratory animals. Also known are a number of tumor antigens that stimulate the formation of antibodies in the patients themselves (for example, p53 mutants, HER-2/neu, CEA, PSA). Their identification, however, is difficult when using conventional methods.

The recent development of a method of analysing (screening) cDNA libraries with sera of patients suffering from various types of tumors, known as SEREX (serological analysis of autologous tumor antigens through the expression of recombinant cDNA, see P.N.A.S. 92, 11810-1995), has led to the identification of a large number of tumor antigens.

The SEREX technology is undoubtedly useful for identifying new tumor antigens, but it presents a number of drawbacks consisting in the very laborious nature of the library screening operations, the high degree of background noise and the large amounts of material necessary.

Since 1993, the year the first tumor antigen (carbonic anhydrase) was characterised, more than 600 different proteins specifically expressed in tumors and to which an immune response is generated have been identified (*M. Pfreundschuch et al. Cancer Vaccine Week, International Symposium, October 5-9, 1998, S03*) and this number is destined to rise still further further [as today SEREX database contains 1695 public sequences (www.licr.org/SEREX.html)]. It is interesting to note that 20-30% of the sequences isolated are as yet unknown gene products.

Further research, however, is necessary to improve the techniques for identifying specific tumor antigens for the treatment of tumors.

Abstract of the invention

It has now been found that a combination of the SEREX technique and phage display, a strategy based on the selection of libraries in which small protein domains are displayed on the surface of bacteriophages, within which the corresponding genetic information is contained, provides a method for the identification of specific tumor antigens by means of the selection of cDNA display libraries with sera. Using this method it proves possible to identify antigens from very large libraries (i.e. which express a large number of different sequences). The antigens thus identified make it possible to obtain specific ligands, which in turn can be used as contrast media.

Therefore, one object of the invention described herein are specific tumor antigens obtainable by a method comprising the identification by means of the selection of cDNA display libraries with sera, said method being characterised in that said selection is accomplished using the phage display technique.

The purpose of the invention described herein is to provide tumor antigens useful for the preparation of medicaments for the treatment of tumor.

Said medicaments are preferably in the form of vaccines.

In another embodiment of the present invention, said antigens are used for the preparation of specific ligands, which can be used for the preparation of medicaments, such as vaccines, or as carriers of antitumor drugs, for example cytotoxic agents or radionuclides.

Detailed description of the invention

The invention described herein comprises the construction of cDNA libraries from tumor cells, obtained both from biopsies (preferable fresh) and from cultured tumor lines, the selection (screening) of such

libraries with autologous and heterologous patient sera to identify tumor antigens, including new ones, the characterisation of said antigens, the generation of specific ligands for said tumor antigens (for example, recombinant human antibodies or humanised recombinant murine antibodies), and the preparation of target-selective medicaments incorporating the ligands generated, optionally carrying antitumor active agents.

The method, according to the invention described herein, advantageously combines the SEREX approach with the potency of the phage-display technique defined above, at the same time avoiding the drawbacks characteristic of the SEREX technique, as outlined above.

What is meant by "phage display" is, as understood by the person of ordinary skill in the art, a strategy based on the selection of libraries in which small protein domains are exposed on the surface of bacteriophages within which is contained the corresponding genetic information.

The method implemented according to the invention described herein provides for the first time new and advantageous analysis possibilities:
- the use of smaller amounts of serum to identify tumor antigens, selecting, prior to screening, the library with sera of patients suffering from tumors, in such a way as to reduce their complexity, enriching it with those clones that express specific antigens;
- owing to technical problems, the direct screening of cDNA libraries, as realised with the state of the art technique, does not allow analysis of a large number of clones (more than approximately one million clones), and thus makes it unsuitable to exploit all the potential of recombinant DNA technology. With the method according to the invention, it is, in fact, possible to construct and analyse libraries 10-100 times larger than those traditionally used in SEREX, thus increasing the likelihood of identifying even those antigens which are present to only a limited extent;

- lastly, the possibility of effecting subsequent selection cycles using sera of different patients or mixtures of sera facilitates the identification of cross-reactive tumor antigens, which constitute one of the main objectives of the invention described herein.

In a library of cDNA cloned in a non-directional manner, it is expected that approximately one-sixth (16.7%) of the proteins produced will be correct. The enrichment of this type of library with the true translation product is the real task of expression/display libraries. The invention described herein also provides a new vector for the expression of cDNA and the display of proteins as fusions with the amino-terminal portion of bacteriophage lambda protein D (pD) with limited expression of "out-of-frame" proteins. According to the vector design, the phage displays the protein fragment on the surface only if its ORF ("Open Reading Frame") coincides with that of pD. The average size of the fragments of cloned DNA in our libraries is 100-600 b.p. (base pairs), and for statistical reasons, most of the "out-of-frame" sequences contain stop codons that do not allow translation of pD and display on the phage surface. In this case, the copy of the lambda genome of wild-type gpD supports the assembly of the capsid. The new expression/display vector (λKM4) for cDNA libraries differs from the one used in SEREX experiments (λgt11) in that the recombinant protein coded for by the cDNA fragment is expressed as a fusion with a protein of the bacteriophage itself and thus is displayed on the capsid.

For each library, messenger RNA of an adequate number of cells, e.g. 10^7 cells, is purified, using common commercially available means, from which the corresponding cDNA has been generated. The latter is then cloned in the expression/display vector λKM4. The amplification of the libraries is accomplished by means of normal techniques known to the expert in the field, e.g. by plating, growth, elution, purification and concentration.

The libraries are then used to develop the conditions required for the selection, "screening" and characterisation of the sequences identified.

A library of the phage-display type, constructed using cDNA deriving from human cells, allows the exploitation of selection by affinity, which is based on the incubation of specific sera with collections of bacteriophages that express portions of human proteins (generally expressed in tumors) on their capsid and that contain within them the corresponding genetic information. Bacteriophages that specifically bind the antibodies present in the serum are easily recovered, in that they remain bound (by the antibodies themselves) to a solid support; the non-specific ones, on the other hand, are washed away.

The "screening", i.e. the direct analysis of the ability of the single phage clones to bind the antibodies of a given serum, is done only at a later stage, when the complexity of the library (i.e. the different number of sequences) is substantially reduced, as a result of the selection.

The use of selection strategies allows faster analysis of a large number of different protein sequences for the purposes of identifying those that respond to a particular characteristic, for example, interacting specifically with antibodies present in the sera of patients with tumors.

Selection by affinity is based on the incubation of specific sera with collections of bacteriophages that express portions of human proteins (generally expressed in tumors) on their capsid and that contain within them the corresponding genetic information. The bacteriophages that specifically bind antibodies present in the serum are easily recovered in that they remain bound (by the antibodies themselves) to a solid support; the non-specific ones, on the other hand, are washed away.

The "screening", i.e. the direct analysis of the ability of the single phage clones to bind the antibodies of a given serum, is done only at a later stage, when the complexity of the library (i.e. the different number of sequences) is substantially reduced, as a result of the selection.

This makes it possible to reduce the work burden and, above all, to use a lower amount of serum for each analysis.

The direct "screening" of a classic cDNA library, in fact, entails the use of large amounts of serum, which are not always easy to procure; in order to analyse the whole complexity of a library (about 10^6 different sequences), one would have to incubate with the sera different filters onto which recombinant proteins, expressed in lysis plaques of infected bacteria, have been transferred: on each filter, it is possible to analyse no more than 10^4 plaques (therefore, at least 100-1000 filters having 15 cm diameter would be necessary) and a 5-10 ml serum volume is used for each filter at a 1:1000 serum dilution (0.5-10 ml total serum).

This strategy, moreover, does not allow the identification of antigens which are present in only slight amounts in the library or are recognised by antibodies present in low concentrations.

On the contrary, affinity selection allows the analysis of more than 10^{11} phage particles in a small volume (0.1-1.1 ml), thereby reducing the required amount of serum: with only 10 µl of serum for each reaction, one can work with a concentration of 10- to 100-fold greater than the one used direct screening, consequently increasing also the probability of identifying those antigens regarded as difficult (considering that one normally performs two selection cycles and one screening on 82 mm filters, the total overall consumption of serum in this case is only 40 µl).

It is thus possible to use selection strategies that favour the identification of antigens capable of interacting with the antibodies present in sera of different patients affected by the same type of tumor (cross-reactive antigens).

Various protocols can be adopted based on the use of different solid supports. These protocols are known to experts in the field.

Various protocols can be used based on the use of different solid supports, such as, for example:
- sepharose: the serum antibodies with the bound phages are attached to a sepharose resin coated with protein A which specifically recognises the immunoglobulins. This resin can be washed by means of brief centrifuging operations to eliminate the aspecific component;
- magnetic beads: the serum antibodies with the bound phages are recovered using magnetic beads coated with human anti-IgC polyclonal antibodies. These beads are washed, attaching them to the test tube wall with a magnet;
- Petri dishes: the serum antibodies with the bound phages are attached to a Petri dish previously coated with protein A. The dish is washed by simply aspirating the washing solution.

The invention will now be illustrated in greater detail by means of examples and figures, Figure 1 representing the map of vector λKM4.

EXAMPLE

Phages and plasmids:

Plasmid pGEX-SN was constructed by cloning the DNA fragment deriving from the hybridisation of the synthetic oligonucleotides K108 5'-GATCCTTACTAGTTTTAGTAGCGGCCGCGGG-3' and K109 5'-AA-TTCCCGCGGCCGCTACTAAAACTAGTAAG-3' in the BamHI and EcoRI sites of plasmid pGEX-3X (*Smith D.B. and Johnson K.S. Gene, 67(1988) 31-40*).

Plasmid pKM4-6H was constructed by cloning the DNA fragment deriving from the hybridisation of the synthetic oligonucleotides K106 5'-GACCGCGTTTGCCGGAACGGCAATCAGCATCGTTCACCACCAC-CACCACCACTAATAGG-3' and K107 5'-AATTCCTATTAGTGGTGGT-GGTGGTGGTGAACGATGCTGATTGCCGTTCCGGCAAACGCG-3' in the RsrII and EcoRI sites of plasmid pKM4.

Selection by affinity

Falcon plates (6 cm, Falcon 1007) were coated for one night at 4°C with 3 ml of 1 μg/ml of protein A (Pierce, #21184) in $NaHCO_3$ 50 mM, pH 9.6. After discarding the coating solution, the plates were incubated with 10 ml of blocking solution (5% dry skimmed milk in PBS x 1, 0.05% Tween 20) for 2 hours at 37°C. 10 μl of human serum were preincubated for 30 minutes at 37°C under gentle agitation with 10 μl of BB4 bacterial extract, and 10 μl of $MgSO_4$ 1M in 1 ml of blocking solution. Approximately 10^{10} phage particles of the library were added to the serum solution for a further 1 hour incubation at 37°C under gentle agitation. The incubation mixtures were plated on plates coated with protein A and left for 30 minutes at room temperature. The plates were rinsed several times with 10 ml of washing solution (1 x PBS, 1% Triton, 10 mM $MgSO_4$). The bound phages were recovered by infection of BB4 cells added directly to the plate (600 μl per plate). 10 ml of molten NZY-Top Agar (48-50°C) were added to the infected cells and immediately poured onto NZY plates (15 cm). The next day, the phages were collected by incubating the plates with agitation with 15 ml of SM buffer for 4 hours at 4°C. The phages were purified by PEG and NaCl precipitation and stored in one tenth of the initial volume of SM with 0.05% sodium azide at 4°C.

Immunoscreening

The phage plaques of the bacterial medium were transferred onto dry nitrocellulose filters (Schleicher & Schuell) for 1 hour at 4°C. The filters were blocked for 1 hour at room temperature in blocking buffer (5% dry skimmed milk in PBS x 1, 0.05% Tween 20). 20 μl of human serum were preincubated with 20 μl of BB4 bacterial extract, 10^9/ml of wild-type lambda phage in 4 ml of blocking buffer. After discarding the blocking solution, the filters were incubated with serum solution for 2 hours at room temperature with agitation. The filters were washed several times with PBS x 1, 0.05% Tween 20 and incubated with human anti-IgG secondary

antibodies conjugated with alkaline phosphatase (Sigma A 2064) diluted 1:5000. Then the filters were washed as above, rinsed briefly with substrate buffer (100 mM Tris-HCl, pH 9.6, 100 mM NaCl, 5 mM $MgCl_2$). Each filter was incubated with 10 ml of substrate buffer containing 330 mg/ml nitro blue tetrazolium, 165 mg/ml 5-bromo-4-chloro-3-indolylphosphate. Reaction was stopped by water washing.

Preparation of lambda phage on large scale (from lysogenic cells)

The BB4 cells were grown up to OD_{600} = 1.0 in LB containing maltose 0.2% with agitation, recovered by centrifugation and resuspended in SM buffer up to OD_{600} = 0.2. 100 µl of cells were infected with lambda with a low multiplicity of infection, incubated for 20 minutes at room temperature, plated on LB agar with ampicillin and incubated for 18-20 hours at 32°C. The next day, a single colony was incubated in 10 ml of LB with ampicillin for one night at 32°C with agitation. 500 ml of fresh LB with ampicillin and $MgSO_4$ 10 mM were inoculated with 5 ml of the overnight culture in a large flask and grown at 32°C up to OD_{600} = 0.6 with vigorous agitation. The flask was incubated for 15 minutes in a water bath at 45°C, then incubated at 37°C in a shaker for a further 3 hours. 10 ml of chloroform were added to the culture to complete the cell lysis and the mixture was incubated in the shaker for another 15 minutes at 37°C. The phage was purified from the lysate culture ac-cording to standard procedures (*Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor*).

The phage lysates for ELISA were prepared from the lysogenic cells by means of a similar procedure, but without the addition of chloroform. After precipitation with NaCl and PEG, the bacteriophage pellet was resuspended in one tenth of the starting volume of SM buffer with sodium azide (0.05%) and stored at 4°C.

Lambda ELISA

Multi-well plates (Immunoplate Maxisorb, Nunc) were coated for one night at 4°C with 100 µl/well of anti-lambda polyclonal antibodies at a 0.7 µg/ml concentration in $NaHCO_3$ 50 mM, pH 9.6. After discarding the coating solution, the plates were incubated with 250 µl of blocking solution (5% dry skimmed milk in PBS x 1, 0.05% Tween 20). The plates were washed twice with washing buffer (PBS x 1, Tween 20). A mixture of 100 µl of blocking buffer and phage lysate (1:1) was added to each well and incubated for 1 hour at 37°C. 1 ml of human serum was incubated for 30 minutes at room temperature with 10^9 plaque forming units (pfu) of phage λKM4, 1 µl of rabbit serum, 1 µl of BB4 extract, 1 µl of FBS in 100 µl of blocking buffer. The plates were washed after incubation with phage lysate and incubated with serum solution for 60 minutes at 37°C. The plates were then washed and goat anti-human HRP conjugated antibody was added (Jackson ImmunoResearch Laboratories), at a dilution of 1:20000, in a blocking buffer/secondary antibody mixture (1:40 rabbit serum in blocking solution). After a 30 minute incubation, the plates were washed and peroxidase activity was measured with 100 µl of TMB liquid substrate system (Sigma). After 15 minutes development, the reaction was stopped with 25 µl of H_2SO_4 2M. The plates were read with an automatic ELISA plate reader and the results were expressed as $A = A_{450nm} - A_{620nm}$. The ELISA data were measured as the mean values of two independent assays.

Construction of λKM4

Plasmid pNS3785 (*Hoess, 1995*) was amplified by inverse PCR with the oligonucleotide sequences KT1 5'-TTTATCTAGACCCAGCCCTAGGAAGCTTCTCCTGAGTAGGACAAATCC-3' bearing sites XbaI and AvrII (underlined) and KT2 5'-GGGTCTAGATAAAACGAAAGGCCCAGTCTTTC-3' bearing XbaI for subsequent cloning in lambda phage. In the inverse PCR, a mixture of Taq polymerase and Pfu DNA polymerase was used to increase the fidelity of the DNA synthesis. Twenty-five amplification cycles were performed (95°C-30 sec, 55°C-30 sec, 72°C-20 min). The self-ligation of the PCR product, previously

digested with XbaI endonuclease, gave rise to plasmid pKM3. The lambda pD gene was amplified with PCR from plasmid pNS3785 using the primers K51 5'-CCGCCTTCCATGGGTACTAGTTTTAAATGCGG-CCGCACGAGCAAAGAAACCTTTAC-3' containing the restriction sites NcoI, SpeI, NotI (underlined) and K86 5'-CTCTCATCCGCCA-AAACAGCC-3'. The PCR product was purified, digested with NcoI and EcoRI restriction endonucleases and re-cloned in the NcoI and EcoRI sites of pKM3, resulting in plasmid pKM4 bearing only the restriction sites SpeI and Not I at extremity 5' of gpD. The plasmid was digested with XbaI enzyme and cloned in the XbaI site of lambda phage λDam15imm21nin5 (Hoess, 1995) (Figure 1).

Construction of cDNA libraries

mRNA was isolated from 10^7 MCF-7 cells (T1 library) or from 0.1 g of a solid tumour sample (T4 library) using a QuickPrep Micro mRNA Purification Kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions. Double-stranded cDNA was synthesised from 5 μg of poly(A)+ RNA using the TimeSaver cDNA Synthesis Kit (Amersham Pharmacia Biotech). Random tagged priming was performed as described previously (Santini, 1986). From 500 ng of double-stranded cDNA the first strand of cDNA copy was synthesised by using the random tagged primer 5'-GCGGCCGCTGG$(N)_9$-3', and the second-strand cDNA copy by using the primer 5'-GGCGGCCAAC-$(N)_9$-3'. The final cDNA product was amplified using oligonucleotides bearing SpeI with three different reading frames and NotI sites to facilitate cloning in the λKM4 lambda vector (5'-GCACTAGTGGCCG-GCCAAC-3', 5'-GCACTAGTCGGCCGGCCAAC-3', 5'-GCACTAGTCG-GGCCGGCCAAC-3' and 5'-GGAGGCTCGAGCGGCCGCTGG-3'). The PCR products were purified on Quiaquick columns (Quiagen) and filtered on Microcon 100 (Amicon) to eliminate the small DNA fragments, digested with SpeI, NotI restriction enzymes, and, after extraction with phenol, filtered again on Microcon 100.

Vector λKM4 was digested with SpeI/NotI and dephosphorylated, and 8 ligation mixtures were prepared for each library, each containing 0.5 mg of vector and approximately 3 ng of insert. After overnight incubation at 4°C the ligation mixtures were packaged *in vitro* with a lambda packaging kit (Ready-To-GoTM Lambda Packaging Kit, Amersham Pharmacia Biotech) and plated in top-agar on 100 (15 cm) NZY plates. After overnight incubation, the phage was eluted from the plates with SM buffer, purified, concentrated and stored at -80°C in 7% DMSO SM buffer.

The complexity of the two libraries, calculated as total independent clones with inserts, was 10^8 for the T1 library and $3.6x10^7$ for the T4 library.

Selection by affinity

For the identification of specific tumour antigens two different affinity selection procedures were used. The first consisted of two panning cycles with a positive serum (i.e. deriving from a patient suffering from tumour pathology), followed by an immunological screening procedure carried out with the same serum, or, alternatively, by analysis of clones taken at random from the mixture of selected phages. A second procedure used a mixture of sera from different patients for the selection, both for panning and for screening, for the purposes of increasing the efficacy of selection of cross-reactive antigens.

The T1 library was selected with 10 positive sera (B9, B11, B13, B14, B15, B16, B17, B18, B19, and B20), generating, after a single selection round, the corresponding pools $p9^I$, $p11^I$, $p13^I$, $p14^I$, $p15^I$, $p16^I$, $p17^I$, $p18^I$, $p19^I$, and $p20^I$. Each pool was then subjected to a second affinity selection round with the same serum, according to the first strategy mentioned above, generating a second series of pools (called $p9^{II}$, $p11^{II}$, $p13^{II}$, $p14^{II}$, $p15^{II}$, $p16^{II}$, $p17^{II}$, $p18^{II}$, $p19^{II}$, and $p20^{II}$). Some of the pools tested in ELISA demonstrated increased reactivity with the corresponding serum, thus confirming the efficacy of the library and of

the affinity selection procedure. Individual clones from pools with increased reactivity ($p9^{II}$, $p13^{II}$, $p15^{II}$, $p19^{II}$, $p20^{II}$) were isolated by immunoscreening with sera used for the selection.

The second procedure mentioned above was applied to the $p13^{II}$ pool, subjecting it to a third selection round with a mixture of sera with the exception of B13 (B11, B14, B15, B16, B17, B18, B19, and B20), and thus selecting cross-reactive clones. The resulting pool ($p13^{III}$) was assayed by ELISA with the same mixture of sera used in the panning. Individual clones from the pool were isolated by immunoscreening with mix ΔB13 (B11, B14, B15, B16, B17, B18, B19, and B20), which made it possible to isolate further positive clones.

Affinity selection experiments were also conducted with the T4 library (and also with the T1 library using different sera) according to the same methodology described here.

Multiple immunological screening (pick-blot analysis)

The individual phage clones which were positive in the immunological screening were isolated and the eluted phages were grown on the lawn of bacteria on plates of 15 cm by picking in arrayed order. The plaques were transferred onto nitrocellulose membranes and subjected to analysis with different positive and negative sera. For the purposes of making the method more robust and reproducible, a Genesys Tekan robotic station was used to pick phages on the plates, which allowed analysis of up to a maximum of 396 individual clones on a membrane of 11 x 7.5 cm, or a lower number of clones repeatedly picked on the same plate cutting the membrane into smaller pieces before incubation with the sera.

Characterisation of positive clones

The clones that presented multiple reactivity, or a greater specificity for the sera of tumour patients as compared to that of healthy donors, were subsequently sequenced and compared with different databases of sequences currently available (Non-Redundant Genbank CDS, Non-Redundant Database of Genbank Est Division, Non-Redundant Genbank+EMBL+DDBJ+PDB Sequences).

The sequences obtained can be classified in six groups:
- sequences that code for epitopes of known breast tumour antigens;
- known sequences that code for epitopes of tumour antigens other than those of breast tumour;
- sequences that code for autoantigens;
- sequences that code for known proteins which are, however, not known to be involved either in tumours or in autoimmune diseases;
- sequences that code for unknown proteins (e.g. EST);
- new sequences not yet present in the databases.

Eighty-one different sequences were identified from the T1 library (called T1-1 to T1-115), 13% of which were unknown proteins and 16% were not present in the databases. Twenty-one sequences were identified from the T4 library (called T4-1 to T4-38), 40% of which were not to be found in the databases. The following table shows, by way of an example, the sequences of some of the clones selected:

Name of clone	Sequence	Identification	Classification
T1-2	ATGGGTACTAGTCGGCCGGCCAA CATCACTCCCACCAATACAATGAC TTCTATGAGAACTACAACCTATTG GCCCACAGCCACAATGATGGAAC CACCTTCATCCACTGTATCAACTA CAGGCAGAGGTCAGACCACCTTT CCAGCTCTACAGCCACATTCCCC AATACCAAACACCCCAGCGGCCG C	Intestinal mucin	Tumor antigen

T1-17	ATGGGTACTAGTCGGGCCGGCCA ACTTGTTGAAGAACTGGATAAAG TGGAATCTCAAGAACGAGAAGAT GTTCTGGCTGGAATGTCTGGAAA ATCCTCTTTCCAAAGATCTGAAGG AGATTTTCTTTTAAGATCATTGAC CAGCGGCCGC	DNA-topo-isomerase II beta	Tumor antigen - malignant mesothelioma
T1-8	ATGGGTACTAGTGGCCGGCCAAC AAGGCAGCTGGAAGAGGTTCTCA AATTAGATCAAGAAATGCCTTTAA CAGAAGTGAAGAGTGAACCTGAG GAAAATATCGATTCAAACAGTGA AAGTGAAAGAGAAGAGATAGAAT TAAAATCTCCGAGGGGACGAAGG AGAATTGCTCGAGATCCCAGCGG CCGC	RBP-1	Tumor antigen - cancer of the breast
T1-6	ATGGGTACTAGTCGGGCCGGCCA ACTTGAGGAGCTGCAGAAGAAAT ACCAGCAAAAGCTAGAGCAGGAG GAGAACCCTGGCAATGATAATGT AACAATTATGGAGCTACAGACAC AGCTAGCACAGAAGACGACTTTA ATCAGTGATTCGAAATTGAAAGA GCAAGAGTTCAGAGAACAGATTC ACAATTTAGAAGACCGTTTGAAG AAATATGAAAAGAATGTATATGC AACAACTGTGGGGACACCTTACA AAGGTGGCAATTTGTACCATACG GATGTCTCACTCTTTGGAGAACCT ACCAGCGGCCGC	Golgin p245	Autoantigen
T1-101	ATGGGTACTAGTCGGCCGGCCAA CTTCGTGGAAATCAGTGAAGATA AAACTAAAATCAGAAGGTCTCCA AGCAAACCCCTACCTGAAGTGAC TGATGAGTATAAAAATGATGTAA AAAACAGATCTGTTTATATTAAAG GCTTCCCAACTGAAGCCAGCGGC CGC	Human lupus La protein	Autoantigen
T1-52	GTGGCCGGCCAACGTTATCAGAG TAGAAGTGGGCATGATCAGAAGA ATCATAGAAAGCATCATGGGAAG AAAAGAATGAAAAGTAAACGATC TACATCATTGTCATCTCCCAGAAA CGGAACCAGCGGCCGC	Binding protein p53	Unknown as tumor antigen
T1-35	ATGGGTACTAGTCGGGCCGGCCA ACAAATTAGGCAGATTGAGTGTG ACAGTGAAGACATGAAGATGAGA GCTAAGCAGCTCCTGGTTGCCTG GCAAGATCAAGAGGGAGTTCATG CAACACCTGAGAATCTGATTAAT GCACTGAATAAGTCTGGATTAAG TGACCTTGCAGAAAGTCCCAGCG GCCGC	Nuclear matrix protein	Unknown as tumor antigen

T1-10	ATGGGTACTAGTGGCCGGCCAAC GGCAGTAGTTCTGGAAAAGCCAC TGGGGACGAGACAGGTGCTAAAG TTGAACGAGCTGATGGAGCTTCA TGGTGAAGGCAGTAGTTCTGGAA AAGCCACTGGGGACGAGACAGGT GCTAAAGTTGAACGAGCTGATGG AATGACCCCCAGCGGCCGC	Ribosomal protein s3a	Unknown as tumor antigen
T1-39	ATGGGTACTAGTGGCCGGCCAAC GAATTATTCGAGTGCTATAGGCG CTTGTCAGGGAGGTAGCGATGAG AGTAATAGATAGGGCTCAGGCGT TTGTTGATGAGATATTTGGAGGT GGGGATGATGCACATAATTTGAA TCAACACAACTCCAGCGGCCGC	No data	
T1-12	ATGGGTACTAGTCGGGCCGGCCA ACGTGGTATTATTTAAAAATAGCT AAAAAGGTAAACAATCCAAATGC CATTAAACAGAGAATTTTAAAAAA TGAGATACTACACAGCAACAAAA ACCTATGAGCTAATGCTAGATGC AACAACACAGACCAGCGGCCGC	No data	
T1-32	ATGGGTACTAGTCGGGCCGGCCA ACTACACGCCTTTCCACTC CACTCTACTACACTCTACTACACT ACACCCAGCGGCCGC	No data	
T1-74	ATGGGTACTAGTCGGCCGGCCAA CAGAGAAGCTAAGCAACTGCATC ATCAGCCACATTCAATCGAATTAA TACAGTCCAGCGGCCGC	EST	
T4-2	ATGGGTACTAGTCGGCCGGCCAA CTCAGAGGTGTATAAGCCAACAT TGCTCTACTCCAGCGGCCGC	EST	
T4-11	ATGGGTACTAGTGGCCGGCCAAC GGTTGGTTTTACTCTAGATTTCAC TGTCGACCCACCCAGCGGCCGC	EST	
T4-19	ATGGGTACTAGTCGGGCCGGCCA ACTATACCGTACAACCCTAACATA TACCAGCGGCCGC	No data	
T5-8	ATGGGTACTAGTCGGGCCGGCCA ACAGAGAGAGCAAGAAAAGAAAA GAAGCCCTCAAGATGTTGAAGTTC TCAAGACAACTACTGAGCTATTTC ATAGCAATGAAGAAAGTGGATTTT TTAATGAACTCGAGGCTCTTAGAG CTGAATCAGTGGCTACCAAAGCA GAACTTGCCAGTTATAAAGAAAAG GCTGAAAAACTTCAAGAAGAACTT TTGGTAAAAGAAACAAATATGACA TCTCTTCAGAAAGACTTAAGCCAA GTTAGGGATCACCAGGGCCGC	AKAP protein	Unknown as tumour antigen

T5-13	ATGGGTACTAGTCGGGCCGGCCA ACACGCATTCGAGCAAATACCAA GTCGCCAGAAGAAAATTTTAGAA GAAGCTCATGAATTGAGTGAAGA TCACTATAAGAAATATTTGGCAAA ACTCAGGTCTATTAATCCACCATG TGTGCCTTTCTTTGGAATTTATCT CACTAATCTCTTGAAAACAGAAGA AGGCAACCCTGAGGTCCTAAAAA GACATGGAAAAGAGCTTATAAACT TTAGCAAAAGGAGGAAAGTAGCA GAAATAACAGGAGAGATCCAGCA GTACCAAAATCAGCCNTACTGTTT ACGAGTAGAATCAGATATCAAAA GGTTCTTTGAAAACTTGAATCCGA TGGGAAATAGCATGGAGAAGGAA TTTACAGATTATCTTTTCAACAAA TCCCTAGAAATAGAACCACGAAAA CCCAGCGGCCGC	SOS1 protein	Unknown as tumour antigen
T5-15	ATGGGTACTAGTCGGGCCGGCCA ACAGGAGAGGTCCTTGGCCCTCT GTGAACCAGGTGTCAATCCCGAG GAACAACTGATTATAATCCAAAGT CGTCTGGATCAGAGTTTGGAGGA GAATCAGGACTTAAAGAAGGAAC TGCTGAAATGTAAACAAGAAGCC AGAAACTTACAGGGGATAAAGGA TGCCTTGCAGCAGAGATTGACTCA GCAGGACACATCTGTTCTTCAGCT CAAACAAGAGCTACTGAGGGCAA ATATGGACAAAGATGAGCTGCAC AACCAGAATGTGGATCTGCAGAG GAAGCTAGATGAGAGGACCCAGC GGCCGC	EST KIAA1735 protein	
T5-18	ATGGGTACTAGTCGGGCCGGCCA ACCGATGTCTGGACATGGGAGTT TTCAAGAGGTGCCACGTCTCCACA CATCAGCACAACTACGCAGCGCC TCCCTCCACTCGGAAGGACTATCC TGCTGCCAAGAGGGTCAAGTTGG ACAGTGTCAGAGTCCTGAGACAG ATCAGCAACAACCGAAAATGCAC CAACCCAGCGGCCGC	mic oncogen, alternative frame	Unknown as tumour antigen

T6-1	ACTAGTCGGGCCGGCCAACGTTAT GAGAAGTCAGATAGTAGCGATAGT GAGTATATCAGTGATGATGAGCAG AAGTCTAAGAACGAGCCAGAAGAC ACAGAGGACAAAGAAGGTTGTCAG ATGGACAAAGAGCCATCTGCTGTT AAAAAAAAGCCCAAGCCTACAAAC CCAGTGGAGATTAAAGAGGAGCTT AAAAGCACGCCACCAGCCAGCGG CCGC	protein kinase C-binding protein	known as cutaneous T-cell lymphoma tumor antigen
T6-2	ACTAGTCGGGCCGGCCAACTTGCC AGGATTCCCTCAGTAACGGCGAGT GAACAGGGAAGAACCAGCGGCCG C	not found	
T6-6	ACTAGTGGGCCGGCCAACGCTGCT CCACCCTCAGCAGATGATAATATC AAGACACCTGCCGAGCGTCTGCGG GGGCCGCTTCCACCCTCAGCGGAT GATAATCTCAAGACACCTTCCGAG CGTCAGCTCACTCCCCTCCCCCCA GCGGCCGC	homologous to PI-3-kinase related kinase SMG-1	Unknown as tumour antigen
T6-7	ACTAGTCGGGCCGGCCAACGGGA ATTGGGAAGGACGGGCCTATATCC CTCCTACAAAGTTCGAGAGAAGAT AGAAACGGTCAAGTACCCCACATA TCCTGAGGCTGAGAAATAAAGCTC AGATGGAAGAGATAAACGACCAAA CTCAGTTCGACCAAACTCAGTTCA AACCATTTGAGCCAAACTGTAGAT GAAGAGGGCTCTGATCTAACAAAA TAAGGTTATATGAGTAGATACTCT CAGCACCAAGAGCAGCTGGGAACT GACATAGGCTTCAATTGGTGGAAT TCCTCTTTAACAAGGGCTGCAATG CCCTCATACCCATGCACAGTACAA TAATGTACTCACATATAACATGCA AAGGTTGTTTTCTACTTTGCCCCTT TCAGTATGTCCCCATAAGACAAAC ACTACCAGCGGCCGC	Fucosyltransferase	Unknown as tumour antigen
T7-1	ACTAGTGTCCTGGAACCCACAAAA GTAACCTTTTCTGTTTCACCGATT GAAGCGACGGAGAAATGTAAGAA AGTGGAGAAGGGTAATCGAGGGC TTAAAAACATACCAGACTCGAAGG AGGCACCTGTGAACCTGTGTAAAC CTAGTTTAGGAAAATCAACAATCA AAACGAATACCCCAATAGGCTGCA AAGTTAGAAAAACTGAAATTATAA GTTACCCAAGTACCAGCGGCCGC	EST KIAA1288 protein	Unknown as tumour antigen

T9-22	ATGGACTTAACAGCTGTTTACAGA ACATTCCACCCAACAATCACAGAA TATACATTCTATTTAACAGTGCAT GGAACTTTTTCCAAGATAGACCAT ATGATAGGCCACAAAACAAGTCTC AATAAGTCTAAGAAAACTGAAATT ATATCAAGTACTCTCTCAGACCAC AGTGGAATAAAATTGGAAAGTAAT TCCAAAAGGAACCCCCAAATCCAT GCCAGCGGCCGC	similar to reverse trascriptase homolog, 50% of identity	
T11-5	ATGCCGATTGACGTTGTTTACACC TGGGTGAATGGCACAGATCTTGAA CTACTGAAGGAACTACAGCAGGTC AGAGAACAGATGGAGGAGGAGCA GAAAGCAATGAGAGAAATCCTTGG GAAAAACACAACGGAACCTACTAA GAAGAGGTCCTACTTTGTGAATTT TCTAGCCGTGTCCAGCGGCCGC	EST unnamed transmembran e protein	
T11-6	ACTAGTGGCCGGCCAACGTATAA AGTAAATATTTCTAAAGCAAAAA CTGCTGTGACGGAGCTCCCTTCT GCAAGGACAGATACAACACCAGT TATAACCAGTGTGATGTCATTGG CAAAAATACCTGCTACCTTATCT ACAGGGAACACTAACAGTGTTTT AAAAGGTGCAGTTACTAAAGAGG CAGCAAAGATCATTCAAGATGAA AGTACACAGGAAGATGCTATGAA ATTTCCATCTTCCCAATCTTCCCA GCCTTCCAGGCTTTTAAAGAACA AAGGCATATCATGCAAACCCGTC ACACATCCCAGCGGCCGC	zinc finger protein 258	Unknown as tumour antigen
T11-9	ACTAGTCGGGCCGGCCAACTTCG ATTTAGTGATCATGCCGTGTTGA AATCCTTGTCTCCTGTAGACCCA GTGGAACCCATAAGTAATTCAGA ACCATCAATGAATTCAGATATGG GAAAAGTCAGTAAAAATGATACT GAAGAGGAAAGTAATAAATCCGC CACAACAGACAATGAAATAAGTA GGACTGAGTATTTATGTGAAAAC TCTCTAGAAGGTAAAAATAAAGA TAATTCTTCAAATGAAGTCTTCC CCCAATATGCCAGCGGCCGC	EST hypotetical human protein	

T11-3	ACTAGTCGGGCCGGCCAACGCAA GCAAAGTTTCCCAAATTCAGATC CTTTACATCAGTCTGATACTTCC AAAGCTCCAGGTTTTAGACCACC ATTACAGAGACCTGCTCCAAGTC CCTCAGGTATTGTCAATATGGAC TCGCCATATGGTTCTGTAACACC TTCTTCAACACATTTGGGAAACT TTGCTTCAAACATTTCAGGAGGT CAGATGTACGGACCTGGGGCACC CCTTGGAGGAGCACCCACCAGCG GCCGC	EST KIAA0697 protein	
T5-2	ATGGGTACTAGTCGGGCCGGCCA ACCCACTTCAGAAAACTATTTGG CAGTAACTACTAAAACTAAACAT AAGCATAGCCTACAACCCAGTAA TGCCAGTATTTCACTCCTAGGTA TATACCCAACCCCCAGCGGCCGC	human genome DNA	
T5-19	ACTAGTCGGGCCGGCCAACGTGA CACACAGACACATGCACATGTGA GTGTATGCGTGCACACACCCCAC CACACCTACAAATACCCCACCAG CGGCCGC	EST	

Clone T1-52 is known as a fragment of binding protein p53 (*Haluska P. et al., NAR, 1999, v. 27, n. 12, 2538-2544*), but has never been identified as a tumour antigen. Said clone has the sequence VLVAGQRYQSRSGHDQKNHRKHHGKKRMKSKRSTSLSSPRNGTS GR and its use as a tumour antigen is part of the invention described herein.

Clone T1-17 is known as a fragment of DNA-topoisomerase II beta identified as malignant mesothelioma tumour antigen (*Robinson C., et al. Am. J. Respir. Cell. Mol. Biol. 2000;22:550-56*). The present invention has identified it as breast cancer tumour antigen. Said clone has the sequence MGTSRAGQLVEELDKVESQEREDVLAGMSGKSS-FQRSEGDFLLRSLTSGR and it use as a breast cancer tumour antigen is part of the invention described herein.

Clone T1-32, hitherto unknown, has the following sequence MGTSRAGQLHAFPLHSTTLYYTTPSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T1-74, hitherto unknown, has the following sequence MGTSRPANREAKQLHHQPHSIELIQSSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T4-2, hitherto unknown, has the following sequence MGTSRPA-NSEVYKPTLLYSSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T4-11, hitherto unknown, has the following sequence MGTSGRPTVGFTLDFTVDPPSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T4-19, hitherto unknown has the following sequence MGTSRAGQLYRTTLTYTSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T1-12, hitherto unknown, has the following sequence MRYYTATKTYELMLDATTQTSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T1-39, hitherto unknown, has the following sequence MRVIDRAQAFVDEIFGGGDDAHNLNQHNSSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T5-8 is known as a fragment of AKAP protein, but has never been identified as a tumour antigen. Said clone has the sequence MGTSRAGQQREQEKKRSPQDVEVLKTTTELFHSNEESGFFNELEA LRAESVATKAELASYKEKAEKLQEELLVKETNMTSLQKDLSQVRD HQGRG and its use as a tumour antigen is part of the invention described herein.

Clone T5-13 is known as as a fragment of SOS1 protein, but has never been identified as a tumour antigen. Said clone has the sequence AGTSRAGQHAFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPP CVPFFGIYLTNLLKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQ

QYQNQYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEP RKPSGR and its use as a tumour antigen is part of the invention described herein.

Clone T5-15 is known as a fragment of EST protein KIAA1735, but has never been identified as a tumour antigen. Said clone has the sequence MGTSRAGQQERSLALCEPGVNPEEQLIIIQSRLDQSLEENQDLKKE LLKCKQEARNLQGIKDALQQRLTQQDTSVLQLKQELLRANMDKDE LHNQNVDLQRKLDERTQRP and its use as a tumour antigen is part of the invention described herein.

Clone T5-18 is known as as a fragment of a mic oncogen, alternative frame, but has never been identified as a tumour antigen. Said clone has the sequence MGTSRAGQPMSGHGSFQEVPRLHTSAQLRSASL-HSEGLSCCQEGQVGQCQSPETDQQQPKMHQPSGR and its use as a tumour antigen is part of the invention described herein.

Clone T6-1 is known as a fragment of protein kinase C-binding protein, identified as cutaneous T-cell lymphoma tumour antigen (*Eichmuller S., et al. PNAS, 2001; 98; 629-34*). The present invention has identified it as breast cancer tumour antigen. Said clone has the sequence TSRAGQRYEKSDSSDSEYISDDEQKSKNEPEDTEDKEGCQMDKEP SAVKKKPKPTNPVEIKEELKSTPPA and its use as a breast cancer tumour antigen is part of the invention described herein.

Clone T6-2 hitherto unknown, has the following sequence TSRAGQLARIPSVTASEQGRT; it is a tumour antigen and as such is part of the invention described herein.

Clone T6-6 is known as a fragment of homologous to PI-3-kinase related kinase SMG-1, but has never been identified as a tumour antigen. Said clone has the sequence TSGPANAAPPSADDNIKTPAE-RLRGPLPPSADDNLKTPSERQLTPLPPAAAK; it is a tumour antigen and as such is part of the invention described herein.

Clone T6-7 is known as a fragment of fucosyltransferase, but has never been identified as a tumour antigen. Said clone has the sequence TSRAGQRELGRTGLYPSYKVREKIETVKYPTYPEAEK; it is a tumour antigen and as such is part of the invention described herein.

Clone T7-1 is known as a fragment of EST protein KIAA1288, but has never been identified as a tumour antigen. Said clone has the sequence TSVLEPTKVTFSVSPIEATEKCKKVEKGNRGLKNIPDSKEAPVNLC KPSLGKSTIKTNTPIGCKVRKTEIISYPSTSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T9-22 is known as a fragment of similar (50% of identity) to reverse trascriptase homolog protein, but has never been identified as a tumour antigen. Said clone has the sequence MDLTAVYRTFHPTITEYTFYLTVHGTFSKIDHMIGHKTSLNKSKKTEIISSTLSDHSGIKLE SNSKRNPQIHASGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T11-5 is known as a fragment of an unnamed transmembrane theoretical protein, but has never been identified as a tumour antigen. Said clone has the sequence MPIDVVYTWVNGTDLELLKELQQVREQMEEEQKAMREILGKNTTEPTKKRSYFVNFLAVSSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T11-6 is known as a fragment of the zinc finger protein 258, but has never been identified as a tumour antigen. Said clone has the sequence TSGRPTYKVNISKAKTAVTELPSARTDTTPVITSVMSLAKIPATLSTGNTNSVLKGAVTKEAAKIIQDESTQEDAMKFPSSQSSQPS RLLKNKGISCKPVTHPSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T11-9 is known as a fragment of a hypotetical human protein, but has never been identified as a tumour antigen. Said clone has the sequence TSRAGQLRFSDHAVLKSLSPVDPVEPISNSEPSMNSDMGKVSKNDTEEESNKSATTDNEISRTEYLCENSLEGKNKDNSSNEVF

PQYASGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T11-3 is known as a fragment of EST protein KIAA0697, but has never been identified as a tumour antigen. Said clone has the sequence TSRAGQRKQSFPNSDPLHQSDTSKAPGFRPPLQRPAPSPSGIVNM-DSPYGSVTPSSTHLGNFASNISGGQMYGPGAPLGGAPTSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T5-2 is known as a fragment of human genome DNA, but has never been identified as a tumour antigen. Said clone has the sequence MGTSRAGQPTSENYLAVTTKTKHKHSLQPSNASISLLGIYPTPSGR; it is a tumour antigen and as such is part of the invention described herein.

Clone T5-19 is known as a fragment of EST protein, but has never been identified as a tumour antigen. Said clone has the sequence TSRAGQRDTQTHAHVSVCVHTPHHTYKYPTSGR; it is a tumour antigen and as such is part of the invention described herein.

It will be understood that, according to the present invention, sequences which are part of known proteins but were unknown as tumor antigen are an object of the present invention as far as their use as tumor antigens is concerned. In the same way, an object of the present invention are the use as tumour antigen of the sequence, or of the entire or part of the product of the gene encoding for said sequence.

The phage clones characterised by means of pick-blot analysis and for which specific reactivity had been demonstrated with sera from patients suffering from breast tumours were amplified and then analysed with a large panel of positive and negative sera. After this ELISA study, the cDNA clones regarded as corresponding to specific tumour antigens were cloned in different bacterial expression systems (protein D and/or GST), for the purposes of better determining their specificity and selectivity. To produce the fusion proteins each clone

was amplified from a single plaque by PCR using the following oligonucleotides: K84 5'-CGATTAAATAAGGAGGAATAAACC-3' and K86 5'-CTCTCATCCGCCAAAACAGCC-3'. The resulting fragment was then purified using the QIAGEN Purification Kit, digested with the restriction enzymes SpeI and NotI and cloned in plasmid pKM4-6H to produce the fusion protein with D having a 6-histidine tail, or in vector pGEX-SN to generate the fusion with GST. The corresponding recombinant proteins were then prepared and purified by means of standard protocols (*Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor*).

The following table gives, by way of an example, the reactivities with negative and positive sera of a number of selected clones, assayed in the form of phage or fusion protein preparations:

Name of clone	Lambda phage reactivity with positive sera (number positive/ total number assayed)	Lambda phage reactivity with negative sera	Reactivity of fusion protein D with positive sera (* for GST fusion)	Reactivity of fusion protein D with negative sera (* for GST fusion)
T1-2	1/20	0/9		
T1-17	1/10	0/0	* 2/16	* 0/15
T1-8	1/10	0/0	1/13	0/15
T1-6	1/10	0/0		
T1-101	/20	0/1		
T1-52	7/41	0/20	13/53	3/24
T1-35	4/10	14/21		
T1-10	1/10	0/0		
T1-39	11/34	0/26	Non- reactive	
T1-12	23/72	0/31	Non- reactive	
T1-32	17/72	0/31	* 10/72	* 1/31
T1-74	29/72	2/27	* 21/72	* 4/32
T4-2	11/18	0/17	9/28	1/31
T4-11	4/21	0/26	8/70	0/30
T4-19	5/20	0/26	12/70	0/30

For the purposes of demonstrating the efficacy of the tumour antigens selected for recognising tumour cells and thus for the detection and diagnosis of pathological abnormalities, mice were immunised to induce an antibody response to a number of the clones selected.

The mice were immunised by giving seven administrations of the antigen over a period of two months, using as immunogens the fusion proteins D1-52, D4-11 and D4-19, corresponding to the fusions of the sequences of clones T1-52, T4-11 and T4-19 with protein D. Each time, 20 μg of protein were injected (intraperitoneally or subcutaneously) per mouse in CFA, 20 μg in IFA, 10 μg in PBS and four times 5 μg in PBS for each of the three proteins. For the purposes of checking the efficacy of immunisation to the sequence of the tumour antigen, the sera of the immunised animals were assayed against the same peptide sequences cloned in different contexts, in order to rule out reactivity to protein D.

In the case of D1-52, the sera of the immunised mice were assayed with the fusions with GST (GST1-52), whereas in the cases of D4-11 and D4-19 the corresponding peptide sequences were cloned in vector

pC89 (*Felici et al. 1991, J. Mol. Biol. 222:301-310*) and then tested as fusions to pVIII (major coat protein of filamentous bacteriophages). The results of ELISA with the sera of the immunised animals showed that effective immunisation was obtained in the cases of D1-52 and D4-11, and thus the corresponding sera were assayed for the ability to recognise tumour cells. To this end, the cell line MCF7 was used, and analysis by FACS demonstrated that antibodies present in both sera (anti-D1-52 and anti-D4-11) are capable of specifically recognising breast tumour MCF7 cells, and not, for instance, ovarian tumour cells, while this recognition capability is not present in preimmune sera from the same mice.

CLAIMS

1. Specific tumor antigens obtainable by selection of cDNA libraries with sera, characterised in that said selection is accomplished with the phage display technique.

2. Tumor antigens according to claim 1, in which said selection is accomplished by means of the SEREX technique (serological analysis of autologous tumor antigens through expression of recombinant cDNA).

3. Tumor antigens according to claim 1 or 2, in which said selection is accomplished by means of the affinity selection technique.

4. Tumor antigens according to claim 1, in which said libraries are obtained from tumor biopsies.

5. Tumor antigens according to claim 1, in which said libraries are obtained from cultured tumor cell lines.

6. Antigen according to claim 6 selected from the group consiting of:
- MGTSRPANREAKQLHHQPHSIELIQSSGR;
- MGTSRPANSEVYKPTLLYSSGR;
- MGTSGRPTVGFTLDFTVDPPSGR;
- MGTSRAGQLYRTTLTYTSGR;
- MGTSRAGQLHAFPLHSTTLYYTTPSGR;
- MRYYTATKTYELMLDATTQTSGR;
- MRVIDRAQAFVDEIFGGGDDAHNLNQHNSSGR.

7. Use as tumor antigen of the sequence or of the entire or part of the product of the gene encoding for said sequenceselected from the group consisting of:
-VLVAGQRYQSRSGHDQKNHRKHHGKKRMKSKRSTSLSSPRNGT-SGR;

-MGTSRAGQQREQEKKRSPQDVEVLKTTTELFHSNEESGFFNELE-
ALRAESVATKAELASYKEKAEKLQEELLVKETNMTSLQKDLSQVR
DHQGRG;

-AGTSRAGQHAFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINP-
PCVPFFGIYLTNLLKTEEGNPEVLKRHGKELINFSKRRKVAEITGEI
QQYQNQYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIE
PRKPSGR;

-MGTSRAGQQERSLALCEPGVNPEEQLIIIQSRLDQSLEENQDLKK-
ELLKCKQEARNLQGIKDALQQRLTQQDTSVLQLKQELLRANMDKD
ELHNQNVDLQRKLDERTQRP;

-MGTSRAGQPMSGHGSFQEVPRLHTSAQLRSASLHSEGLSCCQEG-
QVGQCQSPETDQQQPKMHQPSGR;

-TSRAGQLARIPSVTASEQGRT;

-TSGPANAAPPSADDNIKTPAERLRGPLPPSADDNLKTPSERQLTP-
LPPAAAK;

-TSRAGQRELGRTGLYPSYKVREKIETVKYPTYPEAEK;

-TSVLEPTKVTFSVSPIEATEKCKKVEKGNRGLKNIPDSKEAPVNL-
CKPSLGKSTIKTNTPIGCKVRKTEIISYPSTSGR;

-MDLTAVYRTFHPTITEYTFYLTVHGTFSKIDHMIGHKTSLNKSKK-
TEIISSTLSDHSGIKLESNSKRNPQIHASGR;

-MPIDVVYTWVNGTDLELLKELQQVREQMEEEQKAMREILGKNT-
TEPTKKRSYFVNFLAVSSGR;

-TSGRPTYKVNISKAKTAVTELPSARTDTTPVITSVMSLAKIPATLST-
GNTNSVLKGAVTKEAAKIIQDESTQEDAMKFPSSQSSQPSRLLKNK
GISCKPVTHPSGR;

-TSRAGQLRFSDHAVLKSLSPVDPVEPISNSEPSMNSDMGKVSKN-DTEEESNKSATTDNEISRTEYLCENSLEGKNKDNSSNEVFPQYASGR;

-TSRAGQRKQSFPNSDPLHQSDTSKAPGFRPPLQRPAPSPSGIVNM-DSPYGSVTPSSTHLGNFASNISGGQMYGPGAPLGGAPTSGR;

-MGTSRAGQPTSENYLAVTTKTKHKHSLQPSNASISLLGIYPTPSGR;

-TSRAGQRDTQTHAHVSVCVHTPHHTYKYPTSGR.

8. Use of the antigen or of the entire or part of the product of the gene encoding for said sequence selected from the group consisting of:
-TSRAGQRYEKSDSSDSEYISDDEQKSKNEPEDTEDKEGCQMDKE-PSAVKKKPKPTNPVEIKEELKSTPPA;
-MGTSRAGQLVEELDKVESQEREDVLAGMSGKSSFQRSEGDFLLR-SLTSGR as a breast cancer tumour antigen.

9. Use of antigens of claims 1-8 as active agents useful for the preparation of medicaments for the treatment of tumors.

10. Specific ligand for an antigen of any of claims 1-8.

11. Anti-antigen antibody of one of claims 1-8.

12. Use of a ligand of claim 10 or of an antibody of claim 11 as active agent for the preparation of medicaments for the treatment of tumors.

13. Use of a ligand of claim 10 or of an antibody of claim 11 as carrier for an active agent for the treatment of tumors.

15. Use of the expression/display vector (λKM4) for obtaining antigens of claims 1-8.

16. Antitumor vaccine comprising at least an antigen of claims 1-8.

17. Antitumor medicament comprising a ligand of claim 10.

18. Antitumor medicament comprising an antibody of claim 10.

19. Vaccine for treating breast cancer comprising the antigen of claim 8 and/or a specific ligand thereof and/or a specific antibody thereof.

1/1


HindIII
SpeI
XbaI
AmpR
ColE1
lac I q
Ptrc
gpD
EcoR1
HindIII
T
XbaI
4.7 kb
SpeI
NotI
λ Dam15 imm21 nin5
gpD
Dam15 (amb)
24.5 kb
imm21
nin5
18.7 kb

Figura 1

SEQUENCE LISTING

<110> KENTON SRL

<120> Identification of specific tumour antigens by means of the selection of cDNA libraries with sera and the use of said antigens in the treatment of tumors

<130> PCT-6320

<150> PCT/IT01/005678

<151> 2001-07-27

<160> 72

<170> PatentIn version 3.1

<210> 1

<211> 31

<212> DNA

<213> synthetic oligonucleotide

<400> 1
gatccttact agttttagta gcggccgcgg g
31

<210> 2

<211> 31

<212> DNA

<213> synthetic oligonucloetide

<400> 2
aattcccgcg gccgctacta aaactagtaa g
31

<210> 3

<211> 59

<212> DNA

<213> synthetic oligonucleotide

<400> 3
gaccgcgttt gccggaacgg caatcagcat cgttcaccac caccaccacc actaatagg
59

<210> 4

<211> 60

<212> DNA

<213> synthetic oligonucleotide

<400> 4
aattcctatt agtggtggtg gtggtggtga acgatgctga ttgccgttcc ggcaaacgcg
60

<210> 5

<211> 48

<212> DNA

<213> synthetic oligonucleotide

<400> 5

tttatctaga cccagcccta ggaagcttct cctgagtagg acaaatcc
48

<210> 6

<211> 32

<212> DNA

<213> synthetic oligonucleotide

<400> 6
gggtctagat aaaacgaaag gcccagtctt tc
32

<210> 7

<211> 56

<212> DNA

<213> synthetic oligonucleotide

<400> 7
ccgccttcca tgggtactag ttttaaatgc ggccgcacga gcaaagaaac ctttac
56

<210> 8

<211> 21

<212> DNA

<213> synthetic oligonucleotide

<400> 8
ctctcatccg ccaaaacagc c
21

<210> 9

<211> 12

<212> DNA

<213> synthetic oligonucleotide

<220>

<221> misc_feature

<222> (12)..(12)

<223>

<220>

<221> misc_feature

<222> (12)..(12)

<223> nine residues

<400> 9
gcggccgctg gn
12

<210> 10

<211> 12

<212> DNA

<213> synthetic oligonucleotide

<220>

<221> misc_feature

<222> (12)..(12)

<223> nine residues

<400> 10
ggccggccaa cn
12

<210> 11

<211> 19

<212> DNA

<213> synthetic oligonucleotide

<400> 11
gcactagtgg ccggccaac
19

<210> 12

<211> 20

<212> DNA

<213> synthetic oligonucleotide

<400> 12
gcactagtcg gccggccaac
20

<210> 13

<211> 21

<212> DNA

<213> synthetic oligonucleotide

<400> 13
gcactagtcg ggccggccaa c
21

<210> 14

<211> 21

<212> DNA

<213> synthetic oligonucleotide

<400> 14
ggaggctcga gcggccgctg g
21

<210> 15

<211> 188

<212> DNA

<213> Homo sapiens

<400> 15
atgggtacta gtcggccggc caacatcact cccaccaata caatgacttc tatgagaact
60

acaacctatt ggcccacagc cacaatgatg gaaccacctt catccactgt atcaactaca
120

ggcagaggtc agaccacctt tccagctcta cagccacatt ccccaatacc aaacacccca
180

gcggccgc
188

<210> 16

<211> 150

<212> DNA

<213> Homo sapiens

<400> 16

atgggtacta gtcgggccgg ccaacttgtt gaagaactgg ataaagtgga atctcaagaa
60

cgagaagatg ttctggctgg aatgtctgga aaatcctctt tccaaagatc tgaaggagat
120

tttcttttaa gatcattgac cagcggccgc
150

<210> 17

<211> 150

<212> DNA

<213> Homo sapiens

<400> 17
atgggtacta gtcgggccgg ccaacttgtt gaagaactgg ataaagtgga atctcaagaa
60

cgagaagatg ttctggctgg aatgtctgga aaatcctctt tccaaagatc tgaaggagat
120

tttcttttaa gatcattgac cagcggccgc
150

<210> 18

<211> 312

<212> DNA

<213> Homo sapiens

<400> 18
atgggtacta gtcgggccgg ccaacttgag gagctgcaga agaaatacca gcaaaagcta
60

gagcaggagg agaaccctgg caatgataat gtaacaatta tggagctaca gacacagcta
120

gcacagaaga cgactttaat cagtgattcg aaattgaaag agcaagagtt cagagaacag
180

attcacaatt tagaagaccg tttgaagaaa tatgaaaaga atgtatatgc aacaactgtg
240

gggacacctt acaaaggtgg caatttgtac catacggatg tctcactctt tggagaacct
300

accagcggcc gc
312

<210> 19

<211> 165

<212> DNA

<213> Homo sapiens

<400> 19
atgggtacta gtcggccggc caacttcgtg gaaatcagtg aagataaaac taaaatcaga
60

aggtctccaa gcaaacccct acctgaagtg actgatgagt ataaaaatga tgtaaaaaac
120

agatctgttt atattaaagg cttcccaact gaagccagcg gccgc
165

<210> 20

<211> 132

<212> DNA

<213> Homo sapiens

<400> 20
gtggccggcc aacgttatca gagtagaagt gggcatgatc agaagaatca tagaaagcat
60

catgggaaga aaagaatgaa aagtaaacga tctacatcat tgtcatctcc cagaaacgga
120

accagcggcc gc
132

<210> 21

<211> 189

<212> DNA

<213> Homo sapiens

<400> 21
atgggtacta gtcgggccgg ccaacaaatt aggcagattg agtgtgacag tgaagacatg
60

aagatgagag ctaagcagct cctggttgcc tggcaagatc aagagggagt tcatgcaaca
120

cctgagaatc tgattaatgc actgaataag tctggattaa gtgaccttgc agaaagtccc
180

agcggccgc
189

<210> 22

<211> 180

<212> DNA

<213> Homo sapiens

<400> 22
atgggtacta gtggccggcc aacggcagta gttctggaaa agccactggg gacgagacag
60

gtgctaaagt tgaacgagct gatggagctt catggtgaag gcagtagttc tggaaaagcc
120

actggggacg agacaggtgc taaagttgaa cgagctgatg gaatgacccc cagcggccgc
180

<210> 23

<211> 160

<212> DNA

<213> Homo sapiens

<400> 23
atgggtacta gtggccggcc aacgaattat tcgagtgcta taggcgcttg tcagggaggt
60

agcgatgaga gtaatagata gggctcaggc gtttgttgat gagatatttg gaggtgggga
120

tgatgcacat aatttgaatc aacacaactc cagcggccgc
160

<210> 24

<211> 162

<212> DNA

<213> Homo sapiens

<400> 24
atgggtacta gtcgggccgg ccaacgtggt attatttaaa aatagctaaa aaggtaaaca
60

atccaaatgc cattaaacag agaattttaa aaaatgagat actacacagc aacaaaaacc
120

tatgagctaa tgctagatgc aacaacacag accagcggcc gc
162

<210> 25

<211> 81

<212> DNA

<213> Homo sapiens

<400> 25
atgggtacta gtcgggccgg ccaactacac gcctttccac tccactctac tacactctac
60

tacactacac ccagcggccg c
81

<210> 26

<211> 87

<212> DNA

<213> Homo sapiens

<400> 26
atgggtacta gtcggccggc caacagagaa gctaagcaac tgcatcatca gccacattca
60

atcgaattaa tacagtccag cggccgc
87

<210> 27

<211> 66

<212> DNA

<213> Homo sapiens

<400> 27
atgggtacta gtcggccggc caactcagag gtgtataagc caacattgct ctactccagc
60

ggccgc
66

<210> 28

<211> 69

<212> DNA

<213> Homo sapiens

<400> 28
atgggtacta gtggccggcc aacggttggt tttactctag atttcactgt cgacccaccc
60

agcggccgc
69

<210> 29

<211> 60

<212> DNA

<213> Homo sapiens

<400> 29
atgggtacta gtcgggccgg ccaactatac cgtacaaccc taacatatac cagcggccgc
60

<210> 30

<211> 282

<212> DNA

<213> Homo sapiens

<400> 30
atgggtacta gtcgggccgg ccaacagaga gagcaagaaa agaaaagaag ccctcaagat
60

gttgaagttc tcaagacaac tactgagcta tttcatagca atgaagaaag tggatttttt
120

aatgaactcg aggctcttag agctgaatca gtggctacca aagcagaact tgccagttat
180

aaagaaaagg ctgaaaaact tcaagaagaa cttttggtaa aagaaacaaa tatgacatct
240

cttcagaaag acttaagcca agttagggat caccagggcc gc
282

<210> 31

<211> 435

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (297)..(297)

<223>

<220>

<221> misc_feature

<222> (297)..(297)

<223> different residue

<400> 31
atgggtacta gtcgggccgg ccaacacgca ttcgagcaaa taccaagtcg ccagaagaaa
60

attttagaag aagctcatga attgagtgaa gatcactata agaaatattt ggcaaaactc
120

aggtctatta atccaccatg tgtgcctttc tttggaattt atctcactaa tctcttgaaa
180

acagaagaag gcaaccctga ggtcctaaaa agacatggaa aagagcttat aaactttagc
240

aaaaggagga aagtagcaga aataacagga gagatccagc agtaccaaaa tcagccntac
300

tgtttacgag tagaatcaga tatcaaaagg ttctttgaaa acttgaatcc gatgggaaat
360

agcatggaga aggaatttac agattatctt ttcaacaaat ccctagaaat agaaccacga
420

aaacccagcg gccgc
435

<210> 32

<211> 331

<212> DNA

<213> Homo sapiens

<400> 32
atgggtacta gtcgggccgg ccaacaggag aggtccttgg ccctctgtga accaggtgtc
60

aatcccgagg aacaactgat tataatccaa agtcgtctgg atcagagttt ggaggagaat
120

caggacttaa agaaggaact gctgaaatgt aaacaagaag ccagaaactt acaggggata
180

aaggatgcct tgcagcagag attgactcag caggacacat ctgttcttca gctcaaacaa
240

gagctactga gggcaaatat ggacaaagat gagctgcaca accagaatgt ggatctgcag
300

aggaagctag atgagaggac ccagcggccg c
331

<210> 33

<211> 201

<212> DNA

<213> Homo sapiens

<400> 33
atgggtacta gtcgggccgg ccaaccgatg tctggacatg ggagttttca agaggtgcca
60

cgtctccaca catcagcaca actacgcagc gcctccctcc actcggaagg actatcctgc
120

tgccaagagg gtcaagttgg acagtgtcag agtcctgaga cagatcagca acaaccgaaa
180

atgcaccaac ccagcggccg c
201

<210> 34

<211> 219

<212> DNA

<213> Homo sapiens

<400> 34
actagtcggg ccggccaacg ttatgagaag tcagatagta gcgatagtga gtatatcagt
60

gatgatgagc agaagtctaa gaacgagcca gaagacacag aggacaaaga aggttgtcag
120

atggacaaag agccatctgc tgttaaaaaa aagcccaagc ctacaaaccc agtggagatt
180

aaagaggagc ttaaaagcac gccaccagcc agcggccgc
219

<210> 35

<211> 72

<212> DNA

<213> Homo sapiens

<400> 35

actagtcggg ccggccaact tgccaggatt ccctcagtaa cggcgagtga acagggaaga
60

accagcggcc gc
72

<210> 36

<211> 152

<212> DNA

<213> Homo sapiens

<400> 36
actagtgggc cggccaacgc tgctccaccc tcagcagatg ataatatcaa gacacctgcc
60

gagcgtctgc gggggccgct tccaccctca gcggatgata atctcaagac accttccgag
120

cgtcagctca ctcccctccc cccagcggcc gc
152

<210> 37

<211> 423

<212> DNA

<213> Homo sapiens

<400> 37
actagtcggg ccggccaacg ggaattggga aggacgggcc tatatccctc ctacaaagtt
60

cgagagaaga tagaaacggt caagtacccc acatatcctg aggctgagaa ataaagctca
120

gatggaagag ataaacgacc aaactcagtt cgaccaaact cagttcaaac catttgagcc
180

aaactgtaga tgaagagggc tctgatctaa caaaataagg ttatatgagt agatactctc
240

agcaccaaga gcagctggga actgacatag gcttcaattg gtggaattcc tctttaacaa
300

gggctgcaat gccctcatac ccatgcacag tacaataatg tactcacata taacatgcaa
360

aggttgtttt ctactttgcc cctttcagta tgtccccata agacaaacac taccagcggc
420

cgc
423

<210> 38

<211> 237

<212> DNA

<213> Homo sapiens

<400> 38
actagtgtcc tggaacccac aaaagtaacc ttttctgttt caccgattga agcgacggag
60

aaatgtaaga aagtggagaa gggtaatcga gggcttaaaa acataccaga ctcgaaggag
120

gcacctgtga acctgtgtaa acctagttta ggaaaatcaa caatcaaaac gaatacccca
180

ataggctgca aagttagaaa aactgaaatt ataagttacc caagtaccag cggccgc
237

<210> 39

<211> 228

<212> DNA

<213> Homo sapiens

<400> 39
atggacttaa cagctgttta cagaacattc cacccaacaa tcacagaata tacattctat
60

ttaacagtgc atggaacttt ttccaagata gaccatatga taggccacaa aacaagtctc
120

aataagtcta agaaaactga aattatatca agtactctct cagaccacag tggaataaaa
180

ttggaaagta attccaaaag gaacccccaa atccatgcca gcggccgc
228

<210> 40

<211> 189

<212> DNA

<213> Homo sapiens

<400> 40
atgccgattg acgttgttta cacctgggtg aatggcacag atcttgaact actgaaggaa
60

ctacagcagg tcagagaaca gatggaggag gagcagaaag caatgagaga aatccttggg
120

aaaaacacaa cggaacctac taagaagagg tcctactttg tgaattttct agccgtgtcc
180

agcggccgc
189

<210> 41

<211> 318

<212> DNA

<213> Homo sapiens

<400> 41
actagtggcc ggccaacgta taaagtaaat atttctaaag caaaaactgc tgtgacggag
60

ctcccttctg caaggacaga tacaacacca gttataacca gtgtgatgtc attggcaaaa
120

atacctgcta ccttatctac agggaacact aacagtgttt taaaaggtgc agttactaaa
180

gaggcagcaa agatcattca agatgaaagt acacaggaag atgctatgaa atttccatct
240

tcccaatctt cccagccttc caggctttta aagaacaaag gcatatcatg caaacccgtc
300

acacatccca gcggccgc
318

<210> 42

<211> 273

<212> DNA

<213> Homo sapiens

<400> 42
actagtcggg ccggccaact tcgatttagt gatcatgccg tgttgaaatc cttgtctcct
60

gtagacccag tggaacccat aagtaattca gaaccatcaa tgaattcaga tatgggaaaa
120

gtcagtaaaa atgatactga agaggaaagt aataaatccg ccacaacaga caatgaaata
180

agtaggactg agtatttatg tgaaaactct ctagaaggta aaaataaaga taattcttca
240

aatgaagtct tcccccaata tgccagcggc cgc
273

<210> 43

<211> 258

<212> DNA

<213> Homo sapiens

<400> 43
actagtcggg ccggccaacg caagcaaagt ttcccaaatt cagatccttt acatcagtct
60

gatacttcca aagctccagg ttttagacca ccattacaga gacctgctcc aagtccctca
120

ggtattgtca atatggactc gccatatggt tctgtaacac cttcttcaac acatttggga
180

aactttgctt caaacatttc aggaggtcag atgtacggac ctggggcacc ccttggagga
240

gcacccacca gcggccgc
258

<210> 44

<211> 138

<212> DNA

<213> Homo sapiens

<400> 44
atgggtacta gtcgggccgg ccaacccact tcagaaaact atttggcagt aactactaaa
60

actaaacata agcatagcct acaacccagt aatgccagta tttcactcct aggtatatac
120

ccaaccccca gcggccgc
138

<210> 45

<211> 99

<212> DNA

<213> Homo sapiens

<400> 45
actagtcggg ccggccaacg tgacacacag acacatgcac atgtgagtgt atgcgtgcac
60

acaccccacc acacctacaa ataccccacc agcggccgc
99

<210> 46

<211> 46

<212> PRT

<213> Homo sapiens

<400> 46

Val Leu Val Ala Gly Gln Arg Tyr Gln Ser Arg Ser Gly His Asp Gln
1 5 10 15

Lys Asn His Arg Lys His His Gly Lys Lys Arg Met Lys Ser Lys Arg
20 25 30

Ser Thr Ser Leu Ser Ser Pro Arg Asn Gly Thr Ser Gly Arg
35 40 45

<210> 47

<211> 50

<212> PRT

<213> Homo sapiens

<400> 47

Met Gly Thr Ser Arg Ala Gly Gln Leu Val Glu Glu Leu Asp Lys Val
1 5 10 15

Glu Ser Gln Glu Arg Glu Asp Val Leu Ala Gly Met Ser Gly Lys Ser
20 25 30

Ser Phe Gln Arg Ser Glu Gly Asp Phe Leu Leu Arg Ser Leu Thr Ser
35 40 45

Gly Arg
50

<210> 48

<211> 27

<212> PRT

<213> Homo sapiens

<400> 48

Met Gly Thr Ser Arg Ala Gly Gln Leu His Ala Phe Pro Leu His Ser
1 5 10 15

Thr Thr Leu Tyr Tyr Thr Thr Pro Ser Gly Arg
20 25

<210> 49

<211> 29

<212> PRT

<213> Homo sapiens

<400> 49

Met Gly Thr Ser Arg Pro Ala Asn Arg Glu Ala Lys Gln Leu His His
1 5 10 15

Gln Pro His Ser Ile Glu Leu Ile Gln Ser Ser Gly Arg
20 25

<210> 50

<211> 22

<212> PRT

<213> Homo sapiens

<400> 50

Met Gly Thr Ser Arg Pro Ala Asn Ser Glu Val Tyr Lys Pro Thr Leu
1 5 10 15

Leu Tyr Ser Ser Gly Arg
20

<210> 51

<211> 23

<212> PRT

<213> Homo sapiens

<400> 51

Met Gly Thr Ser Gly Arg Pro Thr Val Gly Phe Thr Leu Asp Phe Thr
1 5 10 15

Val Asp Pro Pro Ser Gly Arg
20

<210> 52

<211> 20

<212> PRT

<213> Homo sapiens

<400> 52

Met Gly Thr Ser Arg Ala Gly Gln Leu Tyr Arg Thr Thr Leu Thr Tyr
1 5 10 15

Thr Ser Gly Arg
20

<210> 53

<211> 23

<212> PRT

<213> Homo sapiens

<400> 53

Met Arg Tyr Tyr Thr Ala Thr Lys Thr Tyr Glu Leu Met Leu Asp Ala
1 5 10 15

Thr Thr Gln Thr Ser Gly Arg
20

<210> 54

<211> 32

<212> PRT

<213> Homo sapiens

<400> 54

Met Arg Val Ile Asp Arg Ala Gln Ala Phe Val Asp Glu Ile Phe Gly
1 5 10 15

Gly Gly Asp Asp Ala His Asn Leu Asn Gln His Asn Ser Ser Gly Arg
20 25 30

<210> 55

<211> 95

<212> PRT

<213> Homo sapiens

<400> 55

Met Gly Thr Ser Arg Ala Gly Gln Gln Arg Glu Gln Glu Lys Lys Arg
1 5 10 15

Ser Pro Gln Asp Val Glu Val Leu Lys Thr Thr Thr Glu Leu Phe His
20 25 30

Ser Asn Glu Glu Ser Gly Phe Phe Asn Glu Leu Glu Ala Leu Arg Ala
35 40 45

Glu Ser Val Ala Thr Lys Ala Glu Leu Ala Ser Tyr Lys Glu Lys Ala
50 55 60

Glu Lys Leu Gln Glu Glu Leu Leu Val Lys Glu Thr Asn Met Thr Ser
65 70 75 80

Leu Gln Lys Asp Leu Ser Gln Val Arg Asp His Gln Gly Arg Gly
85 90 95

<210> 56

<211> 144

<212> PRT

<213> Homo sapiens

<400> 56

Ala Gly Thr Ser Arg Ala Gly Gln His Ala Phe Glu Gln Ile Pro Ser
1 5 10 15

Arg Gln Lys Lys Ile Leu Glu Glu Ala His Glu Leu Ser Glu Asp His
20 25 30

Tyr Lys Lys Tyr Leu Ala Lys Leu Arg Ser Ile Asn Pro Pro Cys Val
35 40 45

Pro Phe Phe Gly Ile Tyr Leu Thr Asn Leu Leu Lys Thr Glu Glu Gly
50 55 60

Asn Pro Glu Val Leu Lys Arg His Gly Lys Glu Leu Ile Asn Phe Ser
65 70 75 80

Lys Arg Arg Lys Val Ala Glu Ile Thr Gly Glu Ile Gln Gln Tyr Gln
85 90 95

Asn Gln Tyr Cys Leu Arg Val Glu Ser Asp Ile Lys Arg Phe Phe Glu
100 105 110

Asn Leu Asn Pro Met Gly Asn Ser Met Glu Lys Glu Phe Thr Asp Tyr
115 120 125

Leu Phe Asn Lys Ser Leu Glu Ile Glu Pro Arg Lys Pro Ser Gly Arg
130 135 140

<210> 57

<211> 110

<212> PRT

<213> Homo sapiens

<400> 57

Met Gly Thr Ser Arg Ala Gly Gln Gln Glu Arg Ser Leu Ala Leu Cys
1 5 10 15

Glu Pro Gly Val Asn Pro Glu Glu Gln Leu Ile Ile Ile Gln Ser Arg
20 25 30

Leu Asp Gln Ser Leu Glu Glu Asn Gln Asp Leu Lys Lys Glu Leu Leu
35 40 45

Lys Cys Lys Gln Glu Ala Arg Asn Leu Gln Gly Ile Lys Asp Ala Leu
50 55 60

Gln Gln Arg Leu Thr Gln Gln Asp Thr Ser Val Leu Gln Leu Lys Gln
65 70 75 80

Glu Leu Leu Arg Ala Asn Met Asp Lys Asp Glu Leu His Asn Gln Asn
85 90 95

Val Asp Leu Gln Arg Lys Leu Asp Glu Arg Thr Gln Arg Pro
100 105 110

<210> 58

<211> 67

<212> PRT

<213> Homo sapiens

<400> 58

Met Gly Thr Ser Arg Ala Gly Gln Pro Met Ser Gly His Gly Ser Phe
1 5 10 15

Gln Glu Val Pro Arg Leu His Thr Ser Ala Gln Leu Arg Ser Ala Ser
20 25 30

Leu His Ser Glu Gly Leu Ser Cys Cys Gln Glu Gly Gln Val Gly Gln
35 40 45

Cys Gln Ser Pro Glu Thr Asp Gln Gln Gln Pro Lys Met His Gln Pro
50 55 60

Ser Gly Arg
65

<210> 59

<211> 70

<212> PRT

<213> Homo sapiens

<400> 59

Thr Ser Arg Ala Gly Gln Arg Tyr Glu Lys Ser Asp Ser Ser Asp Ser
1 5 10 15

Glu Tyr Ile Ser Asp Asp Glu Gln Lys Ser Lys Asn Glu Pro Glu Asp
20 25 30

Thr Glu Asp Lys Glu Gly Cys Gln Met Asp Lys Glu Pro Ser Ala Val
35 40 45

Lys Lys Lys Pro Lys Pro Thr Asn Pro Val Glu Ile Lys Glu Glu Leu
50 55 60

Lys Ser Thr Pro Pro Ala
65 70

<210> 60

<211> 21

<212> PRT

<213> Homo sapiens

<400> 60

Thr Ser Arg Ala Gly Gln Leu Ala Arg Ile Pro Ser Val Thr Ala Ser
1 5 10 15

Glu Gln Gly Arg Thr
20

<210> 61

<211> 52

<212> PRT

<213> Homo sapiens

<400> 61

Thr Ser Gly Pro Ala Asn Ala Ala Pro Pro Ser Ala Asp Asp Asn Ile
1 5 10 15

Lys Thr Pro Ala Glu Arg Leu Arg Gly Pro Leu Pro Pro Ser Ala Asp
20 25 30

Asp Asn Leu Lys Thr Pro Ser Glu Arg Gln Leu Thr Pro Leu Pro Pro
35 40 45

Ala Ala Ala Lys
50

<210> 62

<211> 37

<212> PRT

<213> Homo sapiens

<400> 62

Thr Ser Arg Ala Gly Gln Arg Glu Leu Gly Arg Thr Gly Leu Tyr Pro
1 5 10 15

Ser Tyr Lys Val Arg Glu Lys Ile Glu Thr Val Lys Tyr Pro Thr Tyr
20 25 30

Pro Glu Ala Glu Lys
35

<210> 63

<211> 79

<212> PRT

<213> Homo sapiens

<400> 63

Thr Ser Val Leu Glu Pro Thr Lys Val Thr Phe Ser Val Ser Pro Ile
1 5 10 15

Glu Ala Thr Glu Lys Cys Lys Lys Val Glu Lys Gly Asn Arg Gly Leu
20 25 30

Lys Asn Ile Pro Asp Ser Lys Glu Ala Pro Val Asn Leu Cys Lys Pro
35 40 45

Ser Leu Gly Lys Ser Thr Ile Lys Thr Asn Thr Pro Ile Gly Cys Lys
50 55 60

Val Arg Lys Thr Glu Ile Ile Ser Tyr Pro Ser Thr Ser Gly Arg
65 70 75

<210> 64

<211> 76

<212> PRT

<213> Homo sapiens

<400> 64

Met Asp Leu Thr Ala Val Tyr Arg Thr Phe His Pro Thr Ile Thr Glu
1 5 10 15

Tyr Thr Phe Tyr Leu Thr Val His Gly Thr Phe Ser Lys Ile Asp His
20 25 30

Met Ile Gly His Lys Thr Ser Leu Asn Lys Ser Lys Lys Thr Glu Ile
35 40 45

Ile Ser Ser Thr Leu Ser Asp His Ser Gly Ile Lys Leu Glu Ser Asn
50 55 60

Ser Lys Arg Asn Pro Gln Ile His Ala Ser Gly Arg
65 70 75

<210> 65

<211> 63

<212> PRT

<213> Homo sapiens

<400> 65

Met Pro Ile Asp Val Val Tyr Thr Trp Val Asn Gly Thr Asp Leu Glu
1 5 10 15

Leu Leu Lys Glu Leu Gln Gln Val Arg Glu Gln Met Glu Glu Glu Gln

20 25 30

Lys Ala Met Arg Glu Ile Leu Gly Lys Asn Thr Thr Glu Pro Thr Lys
35 40 45

Lys Arg Ser Tyr Phe Val Asn Phe Leu Ala Val Ser Ser Gly Arg
50 55 60

<210> 66

<211> 106

<212> PRT

<213> Homo sapiens

<400> 66

Thr Ser Gly Arg Pro Thr Tyr Lys Val Asn Ile Ser Lys Ala Lys Thr
1 5 10 15

Ala Val Thr Glu Leu Pro Ser Ala Arg Thr Asp Thr Thr Pro Val Ile
20 25 30

Thr Ser Val Met Ser Leu Ala Lys Ile Pro Ala Thr Leu Ser Thr Gly
35 40 45

Asn Thr Asn Ser Val Leu Lys Gly Ala Val Thr Lys Glu Ala Ala Lys
50 55 60

Ile Ile Gln Asp Glu Ser Thr Gln Glu Asp Ala Met Lys Phe Pro Ser
65 70 75 80

Ser Gln Ser Ser Gln Pro Ser Arg Leu Leu Lys Asn Lys Gly Ile Ser
85 90 95

Cys Lys Pro Val Thr His Pro Ser Gly Arg
100 105

<210> 67

<211> 91

<212> PRT

<213> Homo sapiens

<400> 67

Thr Ser Arg Ala Gly Gln Leu Arg Phe Ser Asp His Ala Val Leu Lys
1 5 10 15

Ser Leu Ser Pro Val Asp Pro Val Glu Pro Ile Ser Asn Ser Glu Pro
20 25 30

Ser Met Asn Ser Asp Met Gly Lys Val Ser Lys Asn Asp Thr Glu Glu
35 40 45

Glu Ser Asn Lys Ser Ala Thr Thr Asp Asn Glu Ile Ser Arg Thr Glu
50 55 60

Tyr Leu Cys Glu Asn Ser Leu Glu Gly Lys Asn Lys Asp Asn Ser Ser
65 70 75 80

Asn Glu Val Phe Pro Gln Tyr Ala Ser Gly Arg
85 90

<210> 68

<211> 86

<212> PRT

<213> Homo sapiens

<400> 68

Thr Ser Arg Ala Gly Gln Arg Lys Gln Ser Phe Pro Asn Ser Asp Pro
1 5 10 15

Leu His Gln Ser Asp Thr Ser Lys Ala Pro Gly Phe Arg Pro Pro Leu
20 25 30

Gln Arg Pro Ala Pro Ser Pro Ser Gly Ile Val Asn Met Asp Ser Pro
35 40 45

Tyr Gly Ser Val Thr Pro Ser Ser Thr His Leu Gly Asn Phe Ala Ser
50 55 60

Asn Ile Ser Gly Gly Gln Met Tyr Gly Pro Gly Ala Pro Leu Gly Gly
65 70 75 80

Ala Pro Thr Ser Gly Arg
85

<210> 69

<211> 46

<212> PRT

<213> Homo sapiens

<400> 69

Met Gly Thr Ser Arg Ala Gly Gln Pro Thr Ser Glu Asn Tyr Leu Ala
1 5 10 15

Val Thr Thr Lys Thr Lys His Lys His Ser Leu Gln Pro Ser Asn Ala
20 25 30

Ser Ile Ser Leu Leu Gly Ile Tyr Pro Thr Pro Ser Gly Arg
35 40 45

<210> 70

<211> 33

<212> PRT

<213> Homo sapiens

<400> 70

Thr Ser Arg Ala Gly Gln Arg Asp Thr Gln Thr His Ala His Val Ser
1 5 10 15

Val Cys Val His Thr Pro His His Thr Tyr Lys Tyr Pro Thr Ser Gly
20 25 30

Arg

<210> 71

<211> 24

<212> DNA

<213> synthetic oligonucleotide

<400> 71
cgattaaata aggaggaata aacc
24

<210> 72

<211> 21

<212> DNA

<213> synthetic oligonucleotide

<400> 72
ctctcatccg ccaaaacagc c
21